Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Supernus Pharmaceuticals Inc Announces Paragraph IV ANDA Filing For Oxtellar XR


Thursday, 27 Jun 2013 08:00am EDT 

Supernus Pharmaceuticals Inc announced that on June 26, 2013 the Company received a Paragraph IV Notice Letter from Watson Laboratories, Inc. (Watson) advising Supernus of the filing by Watson of an Abbreviated New Drug Application seeking approval for oxcarbazepine extended-release tablets. Supernus is currently reviewing the details of this Notice Letter and intends to vigorously enforce its intellectual property rights relating to Oxtellar XR. The product is currently protected by two issued patents that are listed in the FDA's Orange Book. 

Company Quote

8.85
-0.12 -1.34%
29 Jul 2014